Bill Analyses and Ratings
Bill Information: S1390 – 340B Drug Pricing Program Reporting Revisions
Bill Summary
Senate Bill 1390 amends Idaho’s 340B Drug Pricing Program reporting requirements for covered entities — hospitals, clinics, and other federally qualified health providers that purchase discounted drugs under the federal 340B program. The bill shifts the reporting period from the previous calendar year to the most recent fiscal year, and narrows the scope of required financial disclosures to focus specifically on drugs dispensed through contract pharmacies that are not owned or operated by an affiliated 340B entity. It replaces the previous requirement to report aggregate payment amounts received for drugs dispensed to patients with a requirement to report aggregate 340B savings from those contract pharmacy dispensings, and eliminates the former requirement to break down reported data by payer type (commercial, Medicaid, Medicare).
The bill adds a requirement that confidential reports be submitted through a secure website portal rather than by unspecified means, and retains the existing provision that the State Controller’s Office aggregate the data and publish a summary report on the Transparent Idaho website by November 15 each year. The Attorney General retains authority to use the reported information to investigate Medicaid fraud and ensure compliance with federal Health Resources and Services Administration requirements. The bill takes effect July 1, 2026 under an emergency declaration.
Overall Assessment
This bill streamlines and narrows the annual reporting obligations placed on 340B covered entities in Idaho, reducing the volume of data they must submit by eliminating payer-type breakdowns and refocusing disclosures on contract pharmacy activity with non-affiliated pharmacies. Healthcare providers participating in the 340B program face a reduced administrative burden, while state oversight agencies retain the core data needed to detect Medicaid fraud and publish aggregate transparency reports. The practical effect is a lighter compliance load on hospitals and clinics without eliminating public accountability for how 340B savings are used.
Rating Breakdown
ARTICLE I. Responsibility in Government (0)
The bill retains the requirement that the State Controller's Office publish an aggregated report on the Transparent Idaho website, preserving public visibility into how 340B savings are used. However, the bill governs reporting by private and nonprofit healthcare entities to state agencies — not government expenditures, contracts, or audits of government operations — so it neither advances nor undermines core government accountability principles.
ARTICLE II. Citizen Involvement in Government (0)
This bill establishes administrative reporting requirements for healthcare entities participating in a federal drug pricing program. It has no bearing on elections, voting processes, citizen participation mechanisms, or civic engagement.
ARTICLE III. Education (0)
The bill concerns pharmaceutical pricing program reporting by health entities. It contains no provisions related to schools, curriculum, parental rights in education, teacher policy, or education funding.
ARTICLE IV. Agriculture (0)
The bill is limited to 340B drug pricing program reporting requirements. It has no connection to farming, ranching, agricultural markets, or rural land use.
ARTICLE V. Water (0)
The bill addresses healthcare entity reporting obligations and has no provisions related to water rights, water management, inter-basin transfers, or federal interference in state water policy.
ARTICLE VI. Natural Resources and Environment (0)
This bill governs pharmaceutical program reporting and has no connection to natural resource management, environmental regulation, federal land stewardship, or wilderness policy.
ARTICLE VII. Energy (0)
The bill contains no provisions related to energy production, energy independence, utility rates, hydropower, nuclear energy, or any other energy policy matter.
ARTICLE VIII. Idaho National Laboratories (0)
The bill addresses 340B drug pricing program reporting and has no connection to the Idaho National Laboratory, nuclear research, or technology development programs.
ARTICLE IX. Private Property Rights (0)
The bill imposes reporting requirements on healthcare entities but does not involve property ownership, eminent domain, regulatory takings, or any other private property rights issues.
ARTICLE X. State and Federal Lands (0)
The bill is confined to healthcare reporting requirements and has no bearing on state or federal land ownership, management authority, or land transfer policy.
ARTICLE XI. Wildlife Management (0)
The bill addresses pharmaceutical program reporting and contains no provisions related to fish and game management, hunting, predator control, or federal wildlife designations.
ARTICLE XII. Economy (0)
While 340B covered entities are economic actors, the bill's changes are confined to administrative reporting mechanics — shifting the reporting period, narrowing disclosure scope, and adding a secure portal requirement. These changes do not affect commerce, small business regulation, labor policy, or broader economic conditions in Idaho.
ARTICLE XIII. Health and Welfare (0)
The bill reduces the regulatory reporting burden on 340B covered entities — hospitals, federally qualified health centers, and similar providers — by eliminating the payer-type breakdown requirement (formerly requiring separate commercial, Medicaid, and Medicare figures) and narrowing the scope of required disclosures to contract pharmacy activity with non-affiliated pharmacies. This reduction in compliance obligations is partially offset by the new secure portal submission requirement and the retained mandate to report how savings are used for charity care and indigent services, leaving the net regulatory effect on healthcare providers roughly unchanged.
ARTICLE XIV. American Family (0)
The bill addresses pharmaceutical program reporting requirements for healthcare entities. It has no provisions related to family policy, marriage, right to life, parental rights, or child welfare.
ARTICLE XV. Older Americans (0)
The bill modifies administrative reporting requirements for 340B program participants. It contains no provisions specifically affecting older Americans' access to healthcare, retirement security, or employment protections.
ARTICLE XVI. Law and Order with Justice (0)
The bill preserves the Attorney General's authority to use 340B reports for investigating Medicaid fraud, but this is a narrow administrative tool. The bill contains no provisions related to criminal sentencing, gun rights, law enforcement powers, drug enforcement, or the justice system more broadly.
ARTICLE XVII. National Defense - Securing the Border (0)
The bill governs state-level pharmaceutical program reporting and has no connection to national defense, military readiness, border security, veterans' services, or immigration enforcement.
ARTICLE XVIII. Election of Judges and Idaho Supreme Court Justices (0)
The bill addresses 340B drug pricing program reporting requirements and has no bearing on judicial elections, judicial selection processes, or constitutional interpretation principles.
ARTICLE XIX. Religious Liberty (0)
The bill establishes reporting requirements for healthcare entities participating in a federal drug pricing program. It contains no provisions affecting religious exercise, conscience protections, or religious freedom more broadly.